Health care industry
Kimberly-Clark to buy Kenvue in $48.7 billion deal
The company logo for Kenvue Inc. Johnson & Johnson’s consumer-health business is displayed during the company’s initial public offering at the New York Stock Exchange on May 4, 2023. Brendan Mcdermid | Reuters Kimberly-Clark said on Monday it will buy Tylenol-maker Kenvue in a cash-and-stock deal valued at about $48.7 billion, to create one of […]
Read More
Where the blockbuster weight loss drug market stands today — and what’s coming next
A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters The appetite for blockbuster weight loss and diabetes drugs is far from satisfied. From fresh competition to new uses, the market is quickly vaulting into a new stage of […]
Read More
‘Trump effect’ raises hopes for cannabis rally as investors bet on federal reforms, softer marijuana stance
Oils containing CBD (Cannabidiol). Geoffroy Van Der Hasselt | AFP | Getty Images Cannabis stocks could be poised for a rally after years of stagnation, fueled by investor optimism over the possibility for new federal rules for hemp-derived products and signals that President Donald Trump could take a more permissive stance on marijuana. Publicly traded […]
Read More
Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid
Thomas Fuller | SOPA Images | Lightrocket | Getty Images Pfizer said on Friday it had filed a lawsuit against Metsera and Novo Nordisk saying Metsera breached its merger agreement obligations in declaring the Danish drugmaker’s $8.5 billion bid for the U.S. obesity drug developer to be a superior offer. Pfizer asked the Delaware court where it filed the lawsuit to issue a temporary restraining order to […]
Read More
Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]
Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]
Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]
Read More
With demand from women for the hormone surging, Midi Health introduces testosterone therapy
Healthcare expert guiding patient while sitting on sofa in hospital lobby Klaus Vedfelt | Digitalvision | Getty Images Men have long turned to testosterone therapy to address a variety of issues as they age. But in recent years, women are increasingly doing the same, seeing benefits from the hormone in addressing issues around libido, muscular […]
Read More
Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar
Lilly Chair and CEO Dave Ricks speaks during a press conference for Eli Lilly and Company in Houston, Texas, U.S., Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year outlook, as the company continued to see strong demand for its blockbuster […]
Read More
Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit
Merck on Thursday reported third-quarter earnings and revenue that topped estimates as it saw strong demand for its cancer immunotherapy Keytruda. The drugmaker also narrowed its full-year profit outlook to reflect lower estimated tariff costs, among other factors. Sales of Keytruda topped $8 billion for the first time in a quarter, rising 10% from the […]
Read More